Table 4 Summary of T-MPs served as drug carrier for clinical treatment of tumors
From: Application of tumor microparticles in tumor prevention and treatment
Drug carried by T-MPs | Patients | Clinical remission rate | References |
|---|---|---|---|
Cis | Lung cancer with MPE | 100% (3/3) | (Ma et al. 2016a) |
MTX | Lung cancer with MPE | 90.9% (10/11) | (Guo et al. 2019) |
MTX | Lung cancer with MPE | 84.4% (27/32) | (Xu et al. 2020) |
MTX | Lung cancer with MPE | 82.5% (33/40) | (Dong et al. 2022) |
MTX | ECCA | 100% (20/20) | (Gao et al. 2020) |